Last 48 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 20.33 | — | 9.58 | 11.86 | 12.13 | 92.25 | 9.28 | 1665.48 | 12.67 | — | — | 22.49 | 10.54 |
| — | — | +3.3% | -99.3% | -4.2% | — | — | +7304.7% | +20.2% | — | — | +197.3% | +11.8% | |
| P/S Ratio | 2.51 | 2.02 | 2.04 | 2.35 | 2.62 | 2.13 | 2.34 | 3.00 | 2.66 | 2.79 | 3.47 | 4.03 | 3.16 |
| — | -5.3% | -13.0% | -21.5% | -1.2% | -23.7% | -32.5% | -25.5% | -15.9% | -7.9% | +25.6% | +49.6% | +9.2% | |
| P/B Ratio | 1.69 | 1.52 | 1.46 | 1.55 | 1.59 | 1.71 | 1.79 | 1.81 | 1.71 | 1.82 | 1.93 | 2.11 | 2.31 |
| — | -11.0% | -18.7% | -14.4% | -7.0% | -6.1% | -6.9% | -14.2% | -26.0% | -40.7% | -28.5% | -38.2% | -35.7% | |
| P/FCF | — | — | 8.48 | — | 20.32 | 6.52 | 6.84 | — | 102.39 | 9.69 | 17.69 | — | 789.40 |
| — | — | +24.0% | — | -80.2% | -32.7% | -61.3% | — | -87.0% | -0.2% | +45.2% | — | +6171.8% | |
| EV / EBITDA | 7.73 | — | 9.41 | 9.53 | 8.16 | 7.12 | 8.61 | 15.72 | 8.98 | 141.63 | — | 17.35 | 8.15 |
| — | — | +9.3% | -39.4% | -9.1% | -95.0% | — | -9.4% | +10.2% | +1083.5% | — | +191.5% | +11.1% | |
| EV / EBIT | 10.18 | — | 12.30 | 13.40 | 14.82 | 15.95 | 10.53 | 84.20 | 13.42 | — | — | 24.50 | 10.11 |
| — | — | +16.9% | -84.1% | +10.4% | — | — | +243.6% | +32.7% | — | — | +242.3% | +15.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Pfizer Inc.'s operating margin was 21.0% in Q4 2025, down 0.3 pp QoQ and down 11.2 pp YoY. This marks the 4th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 25.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 4.2% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.3% | 70.0% | 74.9% | 64.3% | 71.7% | 73.0% | 60.8% | 62.1% | 70.6% | 41.0% | 21.4% | 64.7% | 67.8% |
| — | -4.2% | +23.2% | +3.6% | +1.6% | +77.9% | +184.2% | -4.0% | +4.0% | -25.5% | -69.0% | -3.9% | +17.1% | |
| Operating Margin | 24.7% | 21.0% | 21.3% | 24.4% | 33.7% | 32.2% | 28.1% | 14.1% | 30.6% | -8.7% | -22.3% | 18.1% | 36.2% |
| — | -34.8% | -24.0% | +72.5% | +10.0% | +471.8% | +226.0% | -21.7% | -15.3% | -139.4% | -152.0% | -61.3% | -7.6% | |
| Net Margin | 12.4% | -9.4% | 21.3% | 19.9% | 21.6% | 2.3% | 25.3% | 0.2% | 21.0% | -22.9% | -17.7% | 17.9% | 30.0% |
| — | -513.7% | -15.9% | +10890.3% | +3.2% | +109.9% | +242.4% | -99.0% | -30.1% | -211.6% | -146.5% | -49.7% | -2.3% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 8.6% | -1.8% | 3.9% | 3.2% | 3.3% | 0.4% | 5.0% | 0.0% | 3.4% | -3.6% | -2.4% | 2.3% | 5.6% |
| — | -497.6% | -21.5% | +12079.3% | -3.5% | +112.4% | +303.4% | -98.9% | -39.0% | -167.8% | -125.5% | -80.0% | -42.8% | |
| ROA | — | — | 1.7% | 1.4% | 1.4% | 0.2% | 2.1% | 0.0% | 1.4% | -1.5% | -1.1% | 1.1% | 2.8% |
| — | — | -16.9% | +12676.4% | +1.0% | +112.3% | +286.6% | -99.0% | -50.6% | -159.5% | -124.9% | -78.5% | -34.5% | |
| ROIC | 9.4% | 2.2% | 1.8% | 1.8% | 2.3% | 2.8% | 2.4% | 0.9% | 2.2% | -0.6% | -1.4% | 1.2% | 3.8% |
| — | -19.2% | -25.9% | +100.7% | +6.9% | +561.7% | +268.4% | -25.2% | -43.3% | -119.3% | -124.4% | -85.3% | -42.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.66 | 0.69 | 0.68 | 0.72 | 0.72 | 0.78 | 0.74 | 0.79 | 0.65 | 0.66 | 0.35 |
| — | — | -7.9% | -11.1% | -8.9% | -9.4% | +10.0% | +18.6% | +115.2% | +118.3% | +70.3% | +47.1% | -18.6% | |
| Debt / EBITDA | — | — | 11.84 | 11.88 | 9.82 | 8.47 | 9.91 | 19.02 | 10.91 | 174.07 | — | 16.65 | 4.27 |
| — | — | +19.5% | -37.5% | -10.0% | -95.1% | — | +14.2% | +155.4% | +3329.0% | — | +500.9% | +36.9% | |
| Current Ratio | — | — | 1.28 | 1.16 | 1.26 | 1.17 | 1.00 | 0.86 | 1.05 | 0.91 | 2.38 | 2.12 | 1.37 |
| — | — | +28.2% | +34.2% | +20.1% | +29.2% | -57.9% | -59.2% | -23.5% | -25.5% | +49.6% | +48.8% | -1.2% | |
| Quick Ratio | — | — | 0.97 | 0.85 | 0.96 | 0.92 | 0.73 | 0.60 | 0.78 | 0.69 | 2.05 | 1.82 | 1.11 |
| — | — | +32.9% | +41.1% | +23.4% | +32.5% | -64.4% | -66.9% | -29.8% | -30.9% | +49.1% | +51.3% | -2.0% | |
| Interest Coverage | 5.78 | 5.19 | 5.44 | 5.47 | 7.07 | 7.75 | 6.34 | 2.42 | 5.77 | -1.83 | -4.33 | 4.63 | 21.02 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonPfizer Inc.'s current P/E is 20.3x. The average P/E over the last 3 quarters is 11.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Pfizer Inc.'s current operating margin is 24.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Pfizer Inc.'s business trajectory between earnings reports.